Ilana Holzman
Director of Investor Relations and Corporate Communications
Replay available
Compugen (NASDAQ:CGEN) Q3 2020 earnings call, held 2020-11-05. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/compugen-ltd-cgen-q3-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Ladies and gentlemen, thank you for standing by. Welcome to Compugen's third quarter 2020 results conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded. I would now like to introduce Ilana Holzman, Compugen's Director of Investor Relations and Corporate Communications.
0:27 Please go ahead. Thank you, Operator, and thank you for joining us today. With me from Compugen are Dr. Anat Cohen-Dayag, President and CEO, Dr. Henry Attaway, Chief Medical Officer, Ari Krashen, CFO and COO, and Dr. Eran Ophir, VP Research and Drug Discovery. Before we begin, I would like to read the following regarding forward-looking statements. During the course of this conference call, the company may make projections and other forward-looking statements regarding future events or future business outlooks. The development efforts and their outcome, our discovery platform, anticipated progress and timeline of our programs, financial and accounting related matters as well as statements regarding our cash position. We wish to caution you that such statements reflect only the company's current expectations and that actual events or results may differ materially. You are kindly referred to the risk factors and cautionary language contained in the documents the company filed with the Securities and Exchange Commission including the company's most recent annual report on Form 20F filed on February 24, 2020.
1:34 The company undertakes no obligation to update projections or forward-looking statements in the future. I will now turn the call over to Anat.
1:45 Thank you, Ilana. Good morning and good afternoon, everyone, and welcome to our third quarter 2020 corporate and financial update. As Ilana mentioned, With me today are Dr. Henry Adewoye, our Chief Medical Officer, Ari Krashen, our CFO and COO, and Dr. Eran Ophir, our VP of Research and Drug Discovery. After my corporate highlights, Henry will review the progress across our clinical programs, followed by Ari's review of our financial statements and position. We will all be available for the Q&A session. Throughout the third quarter of 2020, we continue to advance our clinical programs and execute on our differentiated clinical development strategy with two ongoing clinical programs, COM701 and COM902.
2:46 For these, we currently have four clinical studies, the COM701 Monotherapy Expansion Study and The Doe Descalation Study of COM701 with Bristol-Marie-Squibb's Obdivo for which we have completed enrollment and continue to collect data from patients on study treatment The Triple Combination Study of COM701 with Obdivo and Bristol-Marie-Squibb's anti-tigit antibody and the COM902 Monotherapy Study Our clinical strategy is designed to evaluate the role of the denim axis in immuno-oncology along with a new PVRIG pathway biology that we have identified in order to develop new cancer immunotherapy treatments for patient populations unresponsive to existing drugs.
3:40 I am pleased with our progress keeping these multiple studies on track, especially in these unusual times. With encouraging data We are confident in our approach and in our candidates and strategic clinical path forward. Before I turn the call over to Henry to discuss these trials, I would like to highlight some recent accomplishments that support our unique path and strategy. As a reminder, the foundation of our clinical strategy is our computational discovery of two immune checkpoints in the denim axis, PVRIG and TIGIT. Building on these discoveries and based on our extensive and pioneering research of the denim axis, we believe that these two checkpoint pathways are parallel and complementary inhibitory pathways in the denim axis.
4:52 We have also identified, along with data from others, that there is an intersection between these two pathways and the PD-1 pathway. Further, our data suggests that these three inhibitory pathways have different dominance in different tumor types and patient populations. Accordingly, various patient populations may require the blockade of different combinations of the three pathways This is the underlying rationale for our multiple ongoing clinical studies in various tumor types, all based on the translation of our considerable scientific knowledge of the denim axis, which we continue to expand in our company.
5:44 In line with this, in our last call, I discussed the growing body of evidence that supports the distinct nature of PVRIG and TIGIT. Although these are two complementary pathways, the two targets bind different ligands, have differing levels of expression and dominance across tumor types, and have differential expression across immune cell types. This further supports their non-redundant role and our overall drug combination hypothesis and strategy. As we are continually working to drive a deeper understanding of the denim axis in cancer immunotherapy, in order to further support the strong scientific foundation that has been integral to our efforts and continuously feed our clinical strategy, we were pleased to present new research data at the 2020 TD Therapies Digital Summit held at the end of October.
6:50 This research further supports the distinct biology of PVRIG and TIGIT and the biological rationale of our combination strategy to maximize clinical responses. These data show that PVRIG is expressed on stem-like memory T-cells or TSCM cells that can differentiate into effector T-cells which can directly eliminate tumor cells. Notably, these results indicating PVRIG expression on these cells add to the prior belief that TGIT and PD-1 were the main checkpoints expressed on these cells. TSCM are of growing interest in the field for their possible role in response to immune checkpoint blockade.
7:42 To complement this finding, we also reported that PVRL2, the ligand of PVRIG, is expressed on specialized cells involved in T-cell proliferation, activation, and infiltration into tumors and is also expressed in PD-L1 low, less inflamed tumors. Specifically, PPRL2 is abundantly expressed across dendritic cell types which are associated with efficient T-cell activation as well as tertiary lymphoid structures in two more beds where local T-cell priming occur and which have been previously shown to be associated with response to cancer immunotherapy.
8:31 This data demonstrates for the first time that in addition to TIGIT and PD-1, PVRIG and its ligand PVRL2 are also expressed in and likely play a role in The activity of these increasingly important cells involved in driving an anti-cancer immune response. In addition, these results suggest that PVRIG inhibition may enhance T cell priming and infiltration into inflamed as well as into less inflamed tumors, potentially rendering these tumors more prone to checkpoint blockade. Importantly, Our results provide additional evidence that PVRIG and TGIT have distinct expression patterns and levels of dominance in different tumor types, reinforcing our hypothesis that different cancers or patient populations may require different drug combinations to address these three pathways.
9:37 You can find the complete presentation given at the TGIT Therapies Digital Summit in the publication section on our website. So how does all this science translate to the clinic? This quarter, we were incredibly proud to announce the first patient dose in our biomarker-driven triple combination study, a Phase I-II study, which is evaluating COM701 in combination with Bristol-Mers Squibb's Opdivo and their anti-tigit antibody. The initiation of this trial was a particularly meaningful milestone for COMPIGEN as it marks the clinical evaluation of our underlying science. While combinations of TIGIT and PD-1 inhibitors are being evaluated by others, we are uniquely addressing what we believe is a key component in the genome axis. We believe that the simultaneous blockade of PVRIG, TIGIT, and PD-1 may be required to provide the anti-tumor immune response needed to address non-responsive patient populations in cancers where the three pathways are dominant.
10:51 Importantly, to the best of our knowledge, as the only company with a clinical asset targeting PVRIG and as a leader in the PVRIG space, we are currently the only company capable of applying this approach and testing this hypothesis. were incredibly excited to get started and look forward to providing guidance on our first anticipated data readout from this study in our year-end earning call. As we shared last quarter, we completed enrollment in the fifth and last cohort of the combination dose escalation study of COM701 with Opdivo, and we continue to collect data from patients still on study treatment.
11:37 We are also on track with patient enrollment in our COM701 monotherapy expansion cohort and we look forward to providing data from these studies in the first half of 2021. Moving next to COM902, our anti-TG therapeutic antibody. Our dose escalation study of COM902 is ongoing and we expect to present initial data from the study next year. We also intend to share further information about our development plan for COM902 beyond the dose escalation stage in our year-end earning call. We have been watching the excitement around TIDID grow over the past months and we are pleased to see the clinical validation of this new checkpoint pathway.
12:26 We believe these data provide important validation of our discovery platform as we were among the first groups to discover TIGIT. It also increases our confidence in our overall hypothesis and triple pathway blockade study. In summary, we're highly encouraged by our clinical and preclinical data, which together support our clinical combination strategy and which we believe has the potential to broaden the therapeutic benefit of checkpoint inhibitors to tumor types where they have previously not been successful. Our two clinical stage assets targeting both PVRAG and TIGIT allow us to fully exploit the potential of blocking these pathways, which we believe may ultimately be required to drive robust immune responses in certain tumor types.
13:23 We look forward to continued progress and leveraging our position in the field. The third competent discovered target being evaluated in the clinic is IL-DR2. This program is being developed by Bayer under a research and collaboration agreement. The Phase 1 study is designed to evaluate Bay-195254 as first-in-class anti-IL-DR2 antibody as monotherapy and in combination with Keytruda in patients with advanced solid tumors. Bayer recently updated that the expansion will fully focus on head and neck squamous cell carcinoma. Based on observations during dose escalation, the evolving treatment landscape in immunosensitive solid tumors, and their supportive preclinical data, Bayer decided to focus on treating IO-naive first-line head and neck squamous cell carcinoma patients with a combination of Bay 190-5254 and Keytruda.
14:31 We continue to be encouraged by Bayer's commitment to this program and we look forward to Bayer providing additional data on their progress. Moving next to touch upon some corporate highlights from the quarter, we were very pleased to announce the expansion of our patent portfolio for COM902 with new U.S. and Chinese composition of matter patents. These patents relate to the composition of matter of COM902 alone or in combination with a second antibody targeting an immune checkpoint including PD-1 and PVRIG, specifically COM701. This patent further strengthens our IP portfolio for COM902 which is now covered by Composition of Matter and Use Patents in both US and Europe.
15:27 We were also thrilled to strengthen our incredible scientific advisory board with the appointment of immuno-oncology pioneer, Dr. Nils Lundberg. Dr. Lundberg has over 30 years of experience in the biopharmaceutical industry and his career laid the early foundation for cancer immunotherapy, translating checkpoint inhibition to new therapeutics that have transformed the cancer treatment landscape for millions of patients. We are honored to have him with us and grateful he will be sharing his expertise as we work to advance our programs and vision of expanding the reach of immunotherapies.
16:14 We look forward to 2021 as we continue to gather more data on patients from our ongoing clinical trials, which we believe will provide additional insights into the role of PVRIG within the DNAM access pathway. We are grateful to our team, partners, investigators, and shareholders and look forward to continued progress. With that, I will turn the call over to Henry to review our clinical programs.
16:45 Thank you, Anat, and good day to everyone. As Anat mentioned, we continue to expand and are currently executing multiple studies on our clinical programs. On our COM701 program being conducted in collaboration with BMS, we are evaluating the safety and tolerability of COM701 immunotherapy, and in combination with nivolumab in patients with advanced solid tumors. In addition, we have a phase 1-2 triple combination study evaluating the safety and tolerability of COM701 in combination with BMS 986207, BMS's anti-titted antibody, and nivolumab.
17:30 On our The antithesis antibody program COM902 is being evaluated in a Phase I dose escalation study in patients with advanced solid malignancies. As a reminder, in April, at the oral virtual AACR conference, we reported data from the ongoing Phase I COM701 monotherapy and combination arm with nivolumab. This data included all monotherapy dose escalation cohorts and four or five cohorts from the dual combination arm. We and the investigators were highly encouraged with both safety and tolerability and preliminary anti-tumor activity of COM701 as monotherapy and in combination with nivolumab.
18:16 We reported two confirmed partial responses on the study. In one patient with microsatellite-stable platinum-resistant primary peritoneal cancer on the COM701 monotherapy arm, ongoing for 25 weeks at the time of the presentation. And in a patient with microsatellite-stable colorectal cancer on the COM701 plus nivolumab arm, ongoing for 44 weeks at the time of the data presentation. These confirmed partial responses with durability in tumor types typically unresponsive to immune checkpoint inhibitors were encouraging and demonstrated the potential preliminary activity of COM701 as monotherapy and in combination with nivolumab.
19:02 We also have been encouraged by the durability of responses across all cohorts at the time of the presentation. We reported durable responses of at least stable disease or partial response for over 6 months in 6 out of 28 patients with 4 of 12 patients in the combination arm remaining on study for over 200 days. We have completed enrollment in the fifth and final cohort of the dose escalation combination arm of COM701 with nivolumab and continue to accrue clinical and laboratory data on the patients. We anticipate presenting data at a scientific conference in the first half of 2021. Enrollment is ongoing on the COM701 immunotherapy expansion cohort.
19:50 We anticipate enrollment of 20 patients, that is, four patients per tumor type in this cohort. They will consist of patients with advanced non-sponsored lung, ovarian, breast, endometrial, and colorectal cancer. It is important for us to evaluate the safety and tolerability of COM-701 monotherapy at the recommended dose for expansion, 20 mg per kg IVQ for weeks, in keeping with the primary objective of the study. Further expansion of this monotherapy study in specific indications will be considered as part of the contribution of components based on data gathered in the ongoing COM701 combination studies.
20:36 We aim to present our monotherapy dose expansion data at a scientific conference in the first half of 2021. Regarding the triple combination study that is also being conducted in collaboration with BMS, As Anat mentioned, during the third quarter of 2020, study treatment was initiated in the first patient on the dose escalation arm of the study. This Phase 1-2 study will evaluate the safety, tolerability, and preliminary anti-tumor activity of COM701 in combination with nivolumab and BMS986207. The study consists of two parts, namely dose escalation, part one, and dose expansion, part two.
21:22 In part one, COM-701 will be administered in ascending doses in combination with fixed doses of BMS-986207 and nivolumab. All patients enrolled during dose escalation will have advanced solid tumors and have exhausted or available standard therapies. At the completion of the dose escalation study, a recommended dose for expansion of COM701 with DMS 986207 and nivolumab will be determined. In Part 2, patients will be administered the recommended dose of COM701 in combination with DMS 986207 and nivolumab. Patients will be enrolled into one of three cohorts based on their cancer type.
22:09 Cohort 1 will enroll patients with platinum-resistant slash refractory ovarian cancer, primary peritoneal or fallopian tube cancer. Patients will be randomized one-to-one to receive study treatments with either the three-drug combination or nivolumab monotherapy. Cohort 2 will enroll patients with microsatellite stable endometrial cancer and receive study treatments with the three-drug combination. Cohort 3, which is a basket cohort, will enroll patients with tumors that have high expression of a biomarker, PVRL2, and receive study treatment with a three-drug combination. Subjects with tumor types in cohorts 1 and 2 will not be enrolled into this cohort.
22:58 Additional key objectives of the study include the evaluation of pharmacokinetic parameters and the preliminary antitumor activity of the study drugs. Regarding our biomarker strategy for the ongoing clinical studies, we will evaluate PVRL2 and PVRIG expression retroactively in tumor samples obtained in patients enrolled in the COM701 immunotherapy and triple combination expansion cohorts. In addition, specifically in patients enrolled in the basket cohort of the triple combination study, patients will be required to have tumors that have high expression of PVRL2 prior to enrollment into the cohort. The COM902 Motor Therapy Dose Escalation Study evaluating our antithesis antibody is currently on track and enrolling patients.
23:50 As you know, We made a strategic decision to develop our own antithesis antibody following our understanding of the biology of the DNAM axis. We ultimately will evaluate the combination of COM902 with COM701 as part of a PD1-PDL13 regimen. In our year-end earning call, we intend to share our development plan for COM902 beyond the dose escalation state. I would like to very briefly address the ongoing COVID-19 pandemic. Patient enrollment in our studies has not been significantly adversely impacted by the pandemic, and as indicated by Anat and myself, we expect to meet our previously provided guidance on data readouts in 2021. We and the investigators are committed first and foremost to the safety of patients on our clinical trials.
24:42 and finally, before turning the call over to Ari, I would like to express my gratitude to the patients on our clinical trials and their families, the investigators and clinical trial sites and the excellent work of our hard-working, competent team advancing our clinical programs.
25:00 Ari? Thank you, Henry. Good morning and good afternoon to everyone. Our financial results for the third quarter of 2020 released this morning continue to reflect the solid financial position and expense structure aimed to support our clinical programs in their various stages. R&D expenses for the third quarter of 2020 were $5.5 million compared with $4.3 million for the same period in 2019. Our R&D expenses reflect costs associated with our multiple ongoing clinical programs, which now include the dose escalation of COM701 in combination with Obdivo, the expansion cohort of COM701 monotherapy, the dose escalation study for COM902, and the dose escalation study of the triple combination.
26:00 Net loss for the third quarter of 2020 were $7.8 million, or $0.09 per basic and diluted share, compared with a net loss of $6.5 million, or $0.10 per basic and diluted share, for the same period in 2019. As of September 30, 2020, we had approximately $133 million in cash and cash-related accounts, compared with approximately $136 million as of June 30, 2020. The slight decrease in our cash balances during the third quarter is mostly attributed to approximately $8 million of operating expenses and working capital offset by approximately $5 million of net proceeds received from exercise of warrants and exercise of employee options.
26:58 Going into the fourth quarter of 2020 and beyond, we expect our ongoing R&D expenses to increase slightly as our clinical trials continue to expand and progress. Cash balance at the end of the year is expected to be approximately $124 million. In our next earning call, we will provide a financial outlook for 2021. Thank you for joining today. and on behalf of all of us at Compugen, we hope you stay safe and healthy. And with that, we will now open the call for questions. Thank you, ladies and gentlemen. At this time, we'll begin the question and answer session. If you have a question, please press star one.
27:45 If you wish to cancel your request, please press star two. If you're using speaker equipment, kindly lift the headset before pressing the numbers. Please stand by while we poll for your questions. The first question is from Steven Wiley of Stiefel. Please go ahead. Hi, this is Bonnie. I'm from Stiefel. I wanted to ask about your P1 trial evaluating COM701 monotherapy. You have five different tumor types of four patients per tumor type. Is there any color that you can provide in terms of the strategy or what evidence you'll be that will be compelling to you when you choose which cohorts to upsize later down the line?
28:35 Yes, thank you very much for your question. The primary objective of the study, as you realize, is the safety and tolerability of COM701 at the recommended dose for expansion 20 milligrams per kilogram body weight every four weeks. Therefore, we're focused primarily on ensuring that we follow up on this. The tumor types that we have specified in the expansion cohort are a combination of preclinical data and emerging clinical data that were previously presented first at SITC in 2019 and more recently at the AACR conference by Dr. Ryan Sullivan. So the preclinical data were guided by the tumor types specified as non-sponsored lung cancer, ovarian breast, and endometrial, which we observed have high expression of PDRL2.
29:33 And we added microsatellites to colorectal cancer as a result of the emerging data we saw first at SIPC and more recently at AACR, where we disclosed we had a patient with a partial response that had been ongoing at the time of the presentation for 25 weeks. Going forward, we will continue to monitor this data and as Anat mentioned, and I mentioned in my prepared comments also, additional data disclosures are scheduled for the first half of 2021. Okay, thank you. And for your biomarker analysis from patient biopsies, At what point will you be taking these patient samples? I think it'd be interesting to see, not just for patient selection in your other trials, but with all the preclinical biomarker data that you've shown, it'd be interesting to see the changes in expression of different DM access numbers and if that correlates with response.
30:34 Yes, you're correct. So for the expansion cohorts, specifically I'm referring now to COM701 monotherapy expansion cohorts, One of the requirements for enrollment in the study is the collection of a biopsy prior to treatment and an un-studied biopsy also during the course of treatment. We will examine those results retrospectively and then find out if there's a correlation between expression of PDRL2 and treatment outcomes. And the treatment outcomes I'm referring to are measures such as response rates, and also looking at safety parameters, duration of response, and the correlation with the expression itself of PVRL2, whether it's 1+, 2+, or higher.
31:19 For the expansion cohort, for the basket study, like I mentioned in my prepared comments, that will actually be a prospective collection. We will look at PVRL2 expression in the third cohort, which is the basket cohort, and only patients that have high expression of PVRL2 as we determined centrally will be permitted under this study. So those are our plans. I also mentioned in my prepared comments that we will also look at PVRI-G expression in addition to PVRI-O2 for the ongoing COM701 study. Okay, so is there a comment that you would be able to provide in terms of like when you will be taking these patient samples?
32:03 Yes, the patient samples will be taken for the basket cohort before patients get enrolled under this study. and for the COM701 Motor Therapy Expansion Cohort also before the staff study treatment and during the course of study treatment. Okay, thank you. The next question is from Dayena Gribosh of SVP Learing. Please go ahead. Hi, I have two questions.
32:31 One, I'm wondering if you can talk about the profile of COM701 and COM902 for FC gamma receptor binding and engagement and how it compares perhaps to the other version we see out there in the clinic with IgG1 that are mutated to make them FC functionally incompetent. And I'm asking because given some of the updated data we saw at the TIDGET Summit and in recent publications, specifically from Merck and some from Agenis, that the FC gamma receptor engagement could be through myeloid or dendritic cell binding and not through the traditional recruitment of NK cells and macrophages. I'm just wondering whether the IgG4 backbone in your programs actually would engage that FC gamma receptor on the myeloid population and if we could expect IgG4 to look different than these mutated IgG1 programs.
33:30 And then the second question on the new PVRIG data in the T stem cell memory population. I know there's a recent publication that splits the T memory populations into dysfunctional and functional and showed that the dysfunctional population had really high tidbit and PD-1 expression. And I wonder if you've had a chance to look at PVRIG expression or replicate any of the work in that paper.
33:58 Yes. Thank you, Dana. So for the first question, so IgG4 has some binding to FC-receptors, probably a bit higher than the IgG1 mutated, but overall we expect to have similar patterns. Maybe they're probably going to look similarly. And yes, all these very interesting publications of Agnus and Merck that were shown in the posters in the recent years and they're now in publications, indeed shown the ability or maybe even the requirements in preclinical models of TG to engage FC-receptors in order to mediate this activity. And then this comes to a highly debated question, how this will translate. And for example, for PD-L1, it was published as well that PD-L1 requires FC binding to modulate myeloid cells.
34:44 Very similar MOA, I would say. Maybe not to define details, but roughly the same MOA. PD-L1 was shown to require PD-L1 to modulate myeloid cells in preclinical models. and nowadays in the clinic nobody thinks that the PD-L1 mutated SC binding or the SC competent PD-L1s are inferior. So basically this is for the SC binding question. So probably IG4 similar to the mutated one, but definitely we're not sure that this is going to be translated into clinical efficacy. Again, similar emulation for PD-L1, they did not translate well. And then for the second question, Yes, this one publication did split the TSCM into two populations, one which have PD-1 and TGIT and are maybe developing to more exhausted, and this is actually a very nice publication, but actually there are multiple publications now that shows that the PD-1 responding TSCM are key for checkpoint activity. They respond to checkpoint blockade.
35:46 They are required to checkpoint blockade. This was shown in new clinical models. This was shown by correlation to clinical efficacy of checkpoints. So definitely the field is evolving and is any, you know, new biological field, you can have researchers going into different directions. Overall, I still think that most of the cases shown that the PD-1 digit and what we now see also PVRIG expressing positive TSM are required for a checkpoint activity. Now, the data that we have currently for PVRIG is correlative. We know that PVRL-G has very nice expression by TSTM as PGIT and PD-1. We know that PVRL-2 has very nice expression, actually broader than PD-L1 and PVR on the drittic cells and in tertiary lymphoid structures.
36:34 And indeed, we need to translate either in patient samples or into a preclinical model to translate all these interesting observations also into direct mechanistic studies. But we haven't done so yet.
36:48 Very helpful. Thank you very much. The next question is from Mark Brenenbach of Alpenheimer. Please go ahead.
36:57 Hey, congrats on the continuing progress and thanks for taking my questions. Just a few from me. First of all, do you think the relative dominance of the PVRL-2 checkpoint can be directly inferred from PVRL-2 and PVRL-2 expression profiling? I guess I'm just wondering if there are any downstream signals that we should be looking at to confirm that the inhibitory checkpoint is engaged as you analyze the tumor biopsies.
37:31 Yes, so in terms of signaling, you know, the PVLG signals through an IT domain, the recruitment of phosphatase and et cetera, typical to other checkpoints. It's a new checkpoint, so there's not a lot of studies, so we don't know a lot about, you know, unique signaling. We would expect to have generally, again, increased epithelial filtration, increased TCR repair to our in-patient samples, following treatment, et cetera, due to all these recent observations and biology of PBRL2. I don't think it's the expression level necessarily, but definitely the expression pattern is going to be interesting, and we're also going to try to look at it. You know, maybe responding patients have not only the level of PvRL2, but maybe specific cell population which express PvRL2, like dendritic cells, et cetera, are the ones that are important for response. So we are going to look at all of this and correlate to clinical response eventually.
38:28 Got it. And if the expression is concentrated into these tertiary lymphoid structures, Does that potentially complicate the expression profiling just due to sampling error and factors like that? Or do you anticipate that wouldn't be a problem?
38:47 Well, the expression is not only in the tertiary lymphoid structures. We do see very nice expression in tertiary lymphoid structures, but the expression is also in the tumor cells themselves. The expression is also in dendritic cells, which are not specifically in the tertiary lymphoid structures. So, basically, I don't think this is any complexity. We're going to look at expression across all the different subtypes. Again, it's going to be that the tumor cell level of expression is going to matter. It can be tertiary lymphoid structures, dendritic cells, different subtypes, and eventually, at the end of the day, also PVRIG, expression of T cells, NK cells, etc.
39:25 Okay, got it. And just one last one from me. I'm wondering if you can talk about any of the the data that led Bayer to focus on IO-naive frontline head and neck cancer with the IL-DR2 antibody. And are you anticipating any milestones from Bayer in the next 12 months with respect to this program?
39:48 So, Mark, there's not a lot that we can say about it, except for what is being in the public and what we and Alain Ribert that we can share with the shareholders. But basically, this is based on observations that they had in the dose escalation of their clinical study. Their analysis has been evolving the landscape of I-O treatment and supporting preclinical data. And that was the decision to fully focus on I-O naive first-line head and neck. That's the only information that we can share.
40:34 Obviously, this is a program that is being controlled, handled by Bayer and their decision-making. With respect to milestones, as always, we cannot comment on timing, whether you're going to trigger a milestone or decide, but we will share. and we'll share them most obviously at the time that we obtain
41:03 them. Okay, fair enough. Thanks for taking the question. The next question is from Asika Gunardne of Truist. Please go ahead. Hey there. This is Alan on for Asika. Thank you for taking my question and congratulations on the progress reported. So my question is that given all the large pharma PIDGET presentations that we've seen throughout the year at medical conferences, those presentations haven't really showed very exciting monotherapy activities. And realizing it's early and before your year-end update, I guess we're curious to know what would you like to see in your COMM 902 Phase 1 that would give you the confidence to proceed with the program and maybe to eventually replace the Bristol PIDGET in the triplet study?
41:53 Yeah, thank you, Eleanor. So as you know, this is the first time we're doing a clinical trial with an antithesis antibody, COM902. So for this phase one study, the focus primarily is on safety and tolerability of COM902. And as we do the ascending-dose escalation cohorts, we will keep on accruing data on the patients that are enrolled. And we're all familiar with the data presented by Roche-Tenentex. the data that was previously presented by Mireille Onkomed and more recently the data by Merck regarding the activity of antithesis antibodies either as monotherapy and in combination with the PD-1 or PD-1 inhibitor.
42:40 I cannot comment at this time since we're still accruing data on the monotherapy activities of COM902 in terms of preliminary antitumor activity. but we're cognizant of the fact that in this space now that it appears that combination therapies are the way to go and Compugen is uniquely positioned in that space. In my previous comments I mentioned we will eventually test a PD-1 PD-L1 free regimen So we will keep accruing the data and then observe for preliminary antitumor activity of the agents. You also mentioned something about swapping BMS-986207 into either the triplet combination or so.
43:30 There is no plan to substitute our SIGIT antibody into the triplet combination as is currently being pursued now.
43:43 Yeah, I'll just say that we don't see the competition between the two programs. and we've just expanded the study with BMS. We moved into triplet study and we'll continue to push this forward as much as possible. Our COM902, as Henry said, is really designed in order to test combinations that we can test alone, not as part of the collaboration and mainly COM71 plus COM902 in a PD-1 independent regimen.
44:29 And COM-902 in general allows us to keep the flexibility and really control the two arms of the Dynamaxis. So this is the reason why we have it. It's not in order to compete with the Bristol-Mass. All right, got it. Thanks for taking the question. The next question is from Rennie Benjamin of JMP Securities. Please go ahead. Hi, this is Justin Walsh on for Rennie. It looks like your BMS and BEAR collaborations are moving forward nicely. I was just wondering when we could potentially see an update on your AstraZeneca bispecific program and maybe just remind us about what parameters are public with respect to that partnership.
45:20 Sure, so basically this partnership is a license agreement for AstraZeneca to develop by specific antibodies to one of the programs in our pipeline. We kept the rights for monotherapy and combination therapy and also some bispecific rights and AstraZeneca got the total right for bispecifics other than what we have. As I said, it's a license agreement and under the agreement, AstraZeneca is in charge of of all the R&D and commercial activities. And in addition to the milestone that we got when we entered to this collaboration, were eligible for packages of milestones and royalties for each and every product that is going to be developed based on this license that AstraZeneca obtained. So as such, it is really on AstraZeneca to report any advancements on this program. We will obviously share when we will obtain milestone payments. but we cannot say anything more than that.
46:39 Got it. Thank you. And I guess just one more clarification on the biopsy data. So of course you're going to look for the PVRL2 and PIVRG expression and correlate that to response. I was just wondering if there's anything else specifically that you'll be looking for to identify Responders, or get some sort of a sense of the drug efficacy.
47:13 So basically, we're going to look at multiple parameters. We're going to look at the pathway expression, probably also other typical molecules. We're also going to look at the TME general modulation. We're going to look at TSA sequencing, RNA sex. We're going to try to see look for drug MOA hints of activity along with potential exploratory biomarkers as well. All right. Perfect. Thank you for taking our question. The next question is from Tony Butler of Roth Capital. Please go ahead.
47:50 Yes. Thank you. Good morning. Just back to the biology a little bit, especially with the recent TIGIT Summit. The question is, it's really one, but it has four parts. And the first is around, when you look at overexpression of PBRL2, I'm curious if, in fact, that's in tumors which have already seen, maybe they're second or third line tumors, in other words, they're not front line tumors, so the overexpression is present there. And the question is, If one were to look at a naive patient that maybe even had breast endometrial ovarian cancer, would you also in those naive patients see overexpression of PVRL2 or is that a hypothesis? That's part A. Part B is if you have overexpression of PVRL2 on DC, what's the level of expression of PVR?
48:52 Is it there at all? And then part C is, if you have an overexpression of tigit in T-Rex, would you not think that always using an anti-tigit antibody would be useful? Because this gets into this dominance question yet again. And then finally, in this just stray biology, is there There is some question about PVRL2 binding to PVRIG. Do you get any binding to TIGIT as opposed to PVRIG? In other words, there is some competition, and I just don't know the kinetics behind the differences in the binding. Thanks very much.
49:43 Okay, so for the first question about the expression of PVRL2 on naive patients, well, Actually, PVRL2 is expressed quite broadly. We expect it to be expressed on naive patients, on treated patients. We look at multiple patient samples, both by IC, by flow. We don't expect to see any specific differences between IO-naive or heavily protected patients. The expression is probably going to be there in all patient samples. In terms of the expression of PVRL2 versus PVR on DCs, so there are two subtypes of DCs. One of them is activated disease. These are the subtypes which was highlighted to be the ones which actually captured the antigen, marogated the lymph nodes, activated the T cells over there. So PvRL2 has a very dominant expression on activated disease, but PvR and PdO1 are also expressed in this specific disease subtype.
50:35 So there is co-expression of the three ligands on activated disease, while PvRL2 is more dominant on the activated disease compared to PvR. But then there are also other subtypes of DCs, DC1, DC2, which also played different roles in T cell priming, different publications about all of them very important in T cell priming. So Pvrl2 is expressed also in these subtypes. And again, from what we know at this point, and it's mostly RNA data by now, but multiple data sets, it seems that Pvrl2 has broader expression on the other DC subtypes from Pvr and Pdl1. Then for the third question about CGT on Tregs, So I'm not sure if I got it right, but basically what is nice about TIGIT, that it may be in contrast to some other checkpoints, a blocking antibody on the one hand will stimulate effector T cell activity, but it will also reduce T-Rex suppressive activity.
51:30 So it's not a competition that whether you're going to have some checkpoints, if you block them, actually the T-Rex will be more suppressive. This is not the case for TIGIT as far as we know. So the same blocker antibody will have a double benefit effect, of enhancing T-cell activity and reducing T-rex suppressive activity. And finally, for the question of PVRL2, PVRLG, PVR, so the binding affinity of PVR to TGT is in the nanomolar range. The binding affinity of TGT to PVRL2 is in the micromolar range. And actually, we hardly even saw it when we tried to look at binding, not to mention that when we tried to look functionally, if there is a consequence of PVRL2 binding to TGT, and we didn't see much. On the contrary, PVRL-G binding to PVRL-2 is again nanomolar or tens of nanomolar range and of course we saw in multiple assays that PVRL-2 binding to PVRL-G is functional.
52:27 So basically there is some binding of PVRL-2 to TGIT. We believe this is not dominant, definitely not competing with the dominant binding of PVRL-G to PVRL-2.
52:40 Absolutely perfect. Thank you very much. We have a follow-up question from Diana Graybosh of SBB Learing. Please go ahead.
52:49 Thank you. Thanks for a follow-up. It's actually very related to the last question. I was just wondering if you had any thoughts on some of the recent report of neftin-4 being another ligand for TIGIT and if you think that's at all relevant and you're thinking about that in your development of your TIGIT combination.
53:10 Yes, this is an interesting report. I think it's one publication showing that nectin-4 also binds TGIT. According to that publication, actually, the affinity might be relevant. At this point, we didn't look much into this, and certainly we didn't disclose anything, but we are not sure if it's very relevant. The binding sites of the different nectins are usually similar, so I would expect, but we didn't test, that normal TGIT antibodies block also the binding to nectin-4, but again, we didn't test this, and we didn't look too much into this. Thank you.
53:56 We are very pleased with the steady progress and execution across our clinical program, ensuring all on track to our expected data readout. In addition, starting our triple combination study in parallel to these other studies was an incredibly important milestone advancing our broader science-driven clinical approach to a direct evaluation of our underlying hypothesis. We're excited about what's to come. In 2021, we expect our data readouts to provide additional insights into the role of PVRIG in cancer immunology We also look forward to sharing additional guidance on the triple combination study and development plans for COM902 beyond the monotherapy dose escalation study.
54:52 Thank you again for joining us today and your interest in COMPIGEN. Stay safe and healthy. Thank you. Thank you. This concludes Compugin Ltd.'s third quarter 2020 financial results conference call. Thank you for your participation. You may go ahead and disconnect.
Follow Compugen Ltd. into a list and get an email when it puts out news.
Director of Investor Relations and Corporate Communications
President and CEO
Chief Medical Officer
CFO and COO
VP Research and Drug Discovery
Analyst, SVP Learing
Analyst, Alpenheimer
Analyst, Roth Capital